The FDA will assess safety across the full trial database
Pharmacodynamics: During the MAD phase, after subjects received once-weekly administration of HS-20094 via subcutaneous injection for four consecutive doses, AUC0-2h glucose on day 22 of HS-20094 group was lower than that in placebo group, and there was no significant difference between the two groups in AUC0-2h insulin on day 22
A study using Framingham Heart Study data suggested that men in the study appeared to have a lower risk for dementia due to survival bias, in which the men who survived to age 65 or beyond and were included in the study were the ones with a healthier cardiovascular risk profile (men have a higher rate of death from cardiovascular disease in middle age than women) and thus a lower risk for dementia
Many people experience nausea, early fullness, bloating, reflux, constipation, or diarrhea, especially when starting the medication or increasing the dose
If you experience a drop, you should immediately try to eat easy-to-digest carbohydrates
